The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids.


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 02 11 2020
revised: 08 12 2020
accepted: 19 12 2020
pubmed: 28 1 2021
medline: 14 9 2021
entrez: 27 1 2021
Statut: ppublish

Résumé

A major determinant of β-lactam resistance in methicillin-resistant Staphylococcus aureus (MRSA) is the drug insensitive transpeptidase, PBP2a, encoded by mecA. Full expression of the resistance phenotype requires auxiliary factors. Two such factors, auxiliary factor A (auxA, SAUSA300_0980) and B (auxB, SAUSA300_1003), were identified in a screen against mutants with increased susceptibility to β-lactams in the MRSA strain, JE2. auxA and auxB encode transmembrane proteins, with AuxA predicted to be a transporter. Inactivation of auxA or auxB enhanced β-lactam susceptibility in community-, hospital- and livestock-associated MRSA strains without affecting PBP2a expression, peptidoglycan cross-linking or wall teichoic acid synthesis. Both mutants displayed increased susceptibility to inhibitors of lipoteichoic acid (LTA) synthesis and alanylation pathways and released LTA even in the absence of β-lactams. The β-lactam susceptibility of the aux mutants was suppressed by mutations inactivating gdpP, which was previously found to allow growth of mutants lacking the lipoteichoic synthase enzyme, LtaS. Using the Galleria mellonella infection model, enhanced survival of larvae inoculated with either auxA or auxB mutants was observed compared with the wild-type strain following treatment with amoxicillin. These results indicate that AuxA and AuxB are central for LTA stability and potential inhibitors can be tools to re-sensitize MRSA strains to β-lactams and combat MRSA infections.

Identifiants

pubmed: 33503451
pii: S0924-8579(21)00008-X
doi: 10.1016/j.ijantimicag.2021.106283
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
DNA, Bacterial 0
Lipopolysaccharides 0
Membrane Proteins 0
Penicillin-Binding Proteins 0
Peptidoglycan 0
Teichoic Acids 0
beta-Lactams 0
lipoteichoic acid 56411-57-5
Cefoxitin 6OEV9DX57Y
Amoxicillin 804826J2HU
Octoxynol 9002-93-1
Meropenem FV9J3JU8B1
Oxacillin UH95VD7V76

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106283

Subventions

Organisme : Austrian Science Fund FWF
ID : P 29304
Pays : Austria

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Kasper Mikkelsen (K)

Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark.

Wanchat Sirisarn (W)

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom.

Ohood Alharbi (O)

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom.

Mohanned Alharbi (M)

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom.

Huayong Liu (H)

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom.

Katrine Nøhr-Meldgaard (K)

Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark.

Katharina Mayer (K)

Functional Microbiology, Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine, Vienna, Austria.

Martin Vestergaard (M)

Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark.

Laura A Gallagher (LA)

Department of Microbiology, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.

Jeremy P Derrick (JP)

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom.

Andrew J McBain (AJ)

Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PT, United Kingdom.

Jacob Biboy (J)

Centre for Bacterial Cell Biology, NU Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, United Kingdom.

Waldemar Vollmer (W)

Centre for Bacterial Cell Biology, NU Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4AX, United Kingdom.

James P O'Gara (JP)

Department of Microbiology, School of Natural Sciences, National University of Ireland Galway, Galway, Ireland.

Tom Grunert (T)

Functional Microbiology, Institute of Microbiology, Department of Pathobiology, University of Veterinary Medicine, Vienna, Austria.

Hanne Ingmer (H)

Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark. Electronic address: hi@sund.ku.dk.

Guoqing Xia (G)

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom. Electronic address: guoqing.xia@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH